Gastrointestinal Cancer | Specialty

Pembrolizumab/Trastuzumab Induction Highly Active in HER2+ Gastric, GEJ Cancer

January 18th 2019

Two-thirds of patients with untreated metastatic HER2-positive esophagogastric adenocarcinoma remained free of disease progression at 6 months with a combination of pembrolizumab, trastuzumab, and chemotherapy.

Pembrolizumab Shows OS Benefit in PD-L1+ Esophageal Cancer

January 18th 2019

Pembrolizumab was found to reduce the risk of death by 31% in patients with PD-L1–positive advanced or metastatic esophageal or esophageal junction carcinoma who progressed on standard therapy.

Dr. Narang Discusses Role of Radiation in Pancreatic Cancer

January 18th 2019

Amol K. Narang, MD, assistant professor of radiation oncology and molecular radiation sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, discusses the role of radiation therapy in the treatment of patients with pancreatic cancer.

Dr. O'Donnell on the Importance of Identifying Molecular Subsets in Urothelial Cancer

January 17th 2019

Peter O’Donnell, MD, associate professor of medicine, University of Chicago Medicine, discusses the importance of identifying molecular subsets in urothelial cancer.

Dr. Kopetz on the Rarity of Fusions in CRC

January 17th 2019

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the rarity of fusions in patients with colorectal cancer (CRC).

Abou-Alfa Highlights HCC Advances, Unmet Needs in Other GI Cancers

January 16th 2019

Ghassan K. Abou-Alfa, MD, discusses the rapidly evolving treatment options in hepatocellular carcinoma and other developments in gastrointestinal cancers.

Dr. Choti Discusses Immunotherapy in Pancreatic Cancer

January 16th 2019

Michael A. Choti, MD, chief of surgery, Banner MD Anderson Cancer Center, discusses the role of immunotherapy in the treatment of patients with pancreatic cancer.

Dr. Singal on the FDA Approval of Cabozantinib in HCC

January 15th 2019

Amit G. Singal, MD, associate professor, UT Southwestern Medical Center, discusses the FDA approval of cabozantinib (Cabometyx) for patients with hepatocellular carcinoma (HCC) who previously received sorafenib (Nexavar).

Dr. Sun Discusses the Debate Between Radiation and Chemotherapy in GEJ Cancers

January 15th 2019

Weijing Sun, MD, gastrointestinal oncologist at the University of Kansas School of Medicine, discusses the debate between the use of radiation and chemotherapy in patients with locally advanced gastroesophageal junction (GEJ) adenocarcinoma.

FDA Approves Cabozantinib for Advanced HCC

January 15th 2019

The FDA has approved cabozantinib as a treatment for patients with hepatocellular carcinoma who previously received sorafenib.

Dr. Shields on Optimal Adjuvant Therapy for CRC

January 14th 2019

Anthony Shields, MD, PhD, oncologist, Department of Oncology, Molecular Imaging and Diagnostics Program, Karmanos Cancer Institute, discusses optimal adjuvant therapy for the treatment of patients with colorectal cancer.

Varlitinib Misses Primary Endpoint in Frontline Gastric Cancer Trial

January 14th 2019

Frontline varlitinib (ASLAN001) added to mFOLFOX6 was not found to significantly reduce tumor size after 12 weeks of therapy compared with mFOLFOX6 alone in patients with HER1/HER2 co-expressing advanced or metastatic gastric cancer, missing the primary endpoint of a phase II study.

Dr. Overman Discusses Progress With Immunotherapy in GI Cancer

January 12th 2019

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses progress made with immunotherapy agents in gastrointestinal (GI) cancer.

Dr. Kasi Discusses Treatment Approaches for mCRC

January 10th 2019

Pashtoon M. Kasi, MD, MBBS, MS, an assistant professor of Oncology and senior associate consultant in the Division of Hematology/Oncology, Mayo Clinic, discusses treatment approaches for patients with metastatic colorectal cancer.

Nivolumab Improves OS in Advanced or Recurrent Esophageal Cancer

January 10th 2019

Nivolumab demonstrated a significant extension in overall survival versus chemotherapy in patients with unresectable advanced or recurrent esophageal cancer that is refractory to or intolerant of fluoropyrimidine plus platinum-based therapy.

Dr. Abou-Alfa Discusses New Treatment Options in HCC

January 10th 2019

Ghassan K. Abou-Alfa, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the plethora of new treatment options in hepatocellular carcinoma.

Findings for Pembrolizumab Plus mFOLFOX6 in Advanced CRC

January 9th 2019

Matthew Farren, PhD, post-doctoral fellow, Winship Cancer Institute, Emory University, discusses findings from a multicenter, single-arm phase II clinical trial evaluating the combination of pembrolizumab (Keytruda) and modified leucovorin/5-fluorouracil/oxaliplatin (mFOLFOX6) in patients with advanced colorectal cancer (CRC).

Future Outlook: Improving the Management of NETs

January 7th 2019

Novel Therapies Emerging for the Treatment of NETs

January 7th 2019

Chemotherapy for NETs: Temozolomide

January 7th 2019